71
Participants
Start Date
June 30, 2016
Primary Completion Date
September 30, 2017
Study Completion Date
October 31, 2017
4 mg elamipretide
Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days
40 mg elamipretide
Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days
Placebo
Subcutaneous injection of placebo administered once daily for 28 consecutive days
Centro Cardiologico Monzino U.O. Scompenso, Cardiologia Clinica e Cardiologia Riabilitativa, Milan
Ospedale Niguarda Ca' Granda SC Cardiologia 2, Milan
Cardiologia clinica, Unità dello Scompenso e Terapia intensive Reparto Carlo Magno, Faggi Policlinico di Monza, Monza
A.O. Papa Giovanni XXIII Cardiologia 1, Torre 5, Bergamo
A.O. Spedali Civili di Brescia Cardiologia, Brescia
"Dip. Cardiotoracovascolare: Cardiologia Fondazione IRCCS Policlinico San Matteo Pad. Nuovo Ospedale DEA Degenza: PIANO +3 Ambulatori: P.T. e P+3", Pavia
Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanità Pubblica, Pisa
Azienda Ospedaliera Brotzu Cardiologia, Cagliari
Deventer Hospital, Department of Cardiology, Deventer
University Medical Centre Groningen, Groningen
Anthonius Ziekenhuis, Cardiology Department, Sneek
Elisabeth Twee Steden Hospital (ETZ), Department of Cardiology, Tilburg
Gelre Ziekenhuis Zutphen, Department of Cardiology, Zutphen
Ninewells Hospital and Medical School, Dundee
William Harvey Heart Centre CRC, (Barts Health NHS Trust), London
Stealth BioTherapeutics Inc.
INDUSTRY